Stockreport

PepGen Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

PepGen Inc.  (PEPG) 
PDF – FREEDOM-DM1 15 mg/kg cohort demonstrated the highest mean splicing correction reported to date in DM1 patients –– FREEDOM2-DM1 5 mg/kg cohort on track to readout in Q1 [Read more]